A 5-Year Prospective Observational Registry to Assess Adverse Events of Interest and Effectiveness in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Treated With or Without BENLYSTA (Belimumab)

Trial Profile

A 5-Year Prospective Observational Registry to Assess Adverse Events of Interest and Effectiveness in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Treated With or Without BENLYSTA (Belimumab)

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 20 Jan 2017

At a glance

  • Drugs Belimumab (Primary) ; Antimalarials; Corticosteroids; Immunosuppressants
  • Indications Systemic lupus erythematosus
  • Focus Adverse reactions
  • Acronyms SABLE
  • Sponsors Human Genome Sciences
  • Most Recent Events

    • 12 Oct 2014 Planned End Date changed from 1 Mar 2022 to 1 Apr 2025 as reported by ClinicalTrials.gov record.
    • 12 Oct 2014 Planned primary completion date changed from 1 Mar 2022 to 1 Apr 2025 as reported by ClinicalTrials.gov record.
    • 27 Feb 2014 According to the ClinicalTrials.gov record, status changed from active, no longer recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top